Multiple Myeloma/Plasma Cell Neoplasms - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Comparing Post-transplant Therapies for Multiple Myeloma Patients
(Posted: 09/07/2010) - In this trial, patients age 70 or younger with multiple myeloma will be randomly assigned to treatment with one of three regimens after receiving high-dose melphalan chemotherapy and autologous stem cell transplantation.
- Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.
- Lenalidomide Maintenance Therapy for Multiple Myeloma
(Posted: 02/24/2009) - In this trial, researchers are exploring whether maintenance therapy with lenalidomide after single autologous stem cell transplantation can slow or prevent the return of multiple myeloma in patients who have undergone induction therapy.
- Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
(Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
- New Drugs for Multiple Myeloma Consolidation Therapy
(Posted: 07/08/2008) - In this trial, newly diagnosed multiple myeloma patients who have undergone induction therapy will be treated with consolidation therapy consisting of dexamethasone and the drug bortezomib, and some will also be randomly assigned to receive a third drug called lenalidomide.